Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 18/20 | 0.58 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CCND1 | P24385 | 2/20 | 0.46 |
| ▸ | CCND2 | P30279 | 2/20 | 0.46 |
| ▸ | CCND3 | P30281 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660399 | 0.79 | PAK3 (0.56) | JAK3CCND3 | |
| SCHEMBL660442 | 0.78 | PAK3 (0.52) | JAK3CDK4CCND1CCND2CCND3 | |
| SCHEMBL10192736 | 0.77 | PAK3 (0.53) | JAK3CDK4CCND1CCND2CCND3 | |
| SCHEMBL660218 | 0.76 | CDK4 (0.73) | JAK3CDK4CCND1CCND2CCND3 | |
| SCHEMBL23444641 | 0.74 | JAK3 (0.76) | JAK3CDK4CCND1CCND2CCND3 | |
| SCHEMBL17645062 | 0.74 | EGFR (0.50) | JAK3CDK4CCND1CCND2CCND3 | |
| SCHEMBL23444026 | 0.74 | JAK3 (1.00) | JAK3 | |
| SCHEMBL17536952 | 0.73 | WEE1 (0.64) | CCND3 | |
| SCHEMBL28995531 | 0.73 | JAK3 (0.72) | JAK3 | |
| SCHEMBL23444100 | 0.73 | JAK3 (1.00) | JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | JAK3 2335/4885CDK4 1028/4885CCND1 4465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.